Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

Study acronym: COGFIT
StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Sep 15, 2026 → Sep 15, 2027
See other at-risk trials from Massachusetts General Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 15, 2026 to Sep 15, 2027
    • Eligibility criteria shortened, about 6 words
    • Publications: details revised at 3 of 3 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Individuals with immune thrombocytopenia (ITP) frequently report difficulties with attention and memory. The main question this study seeks to answer is: Do patients with ITP have evidence of cognitive impairment as detected by a cognitive function test battery? To address this issue, participants will take a cognitive function test and complete surveys on quality of life, fatigue, depression, and cognitive symptoms. The primary aim of the study is to evaluate for the presence and extent of cognitive impairment in patients with ITP. The study will also assess whether cognitive impairment in ITP is associated with patient-reported impacts on quality of life, fatigue, mood, and cognitive symptoms as well as clinical characteristics such as ITP disease and treatment history.
Trial Details
NCT Number NCT06817395
Lead Sponsor Massachusetts General Hospital
Collaborators: Platelet Disorder Support Association (PDSA)
Conditions
(from sponsor)		 Immune Thrombocytopenia
Related terms Cognitive Dysfunction, Purpura, Thrombocytopenic, Idiopathic
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov